The FDA has approved atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.
Original Article: FDA Approves Frontline Atezolizumab Regimen for NSCLC